Ertapenem: Difference between revisions
Gerald Chi (talk | contribs) |
Gerald Chi (talk | contribs) mNo edit summary |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Ertapenem}} | {{Ertapenem}} | ||
{{CMG}} | {{CMG}}; {{AE}} {{SS}} | ||
==Overview== | ==Overview== | ||
Ertapenem is a [[carbapenem]] [[antibiotic]] marketed by [[Merck & Co.|Merck]] as INVANZ®. It is structurally very similar to [[meropenem]] in that it possess a 1-β-methyl group. | |||
==Category== | ==Category== | ||
Carbapenem | |||
==US Brand Names== | ==US Brand Names== | ||
INVANZ<sup>®</sup> | INVANZ<sup>®</sup> | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
'''[[Ertapenem description|Description]]''' | |||
''' [[Ertapenem description|Description]]''' | |||
'''| [[Ertapenem clinical pharmacology|Clinical Pharmacology]]''' | '''| [[Ertapenem clinical pharmacology|Clinical Pharmacology]]''' | ||
'''| [[Ertapenem microbiology|Microbiology]]''' | '''| [[Ertapenem microbiology|Microbiology]]''' | ||
'''| [[Ertapenem indications and usage|Indications and Usage]]''' | '''| [[Ertapenem indications and usage|Indications and Usage]]''' | ||
'''| [[Ertapenem contraindications|Contraindications]]''' | '''| [[Ertapenem contraindications|Contraindications]]''' | ||
'''| [[Ertapenem warnings|Warnings and Precautions]]''' | '''| [[Ertapenem warnings and precautions|Warnings and Precautions]]''' | ||
'''| [[Ertapenem adverse reactions|Adverse Reactions]]''' | '''| [[Ertapenem adverse reactions|Adverse Reactions]]''' | ||
'''| [[Ertapenem overdosage|Overdosage]]''' | '''| [[Ertapenem overdosage|Overdosage]]''' | ||
| Line 25: | Line 30: | ||
'''| [[Ertapenem labels and packages|Labels and Packages]]''' | '''| [[Ertapenem labels and packages|Labels and Packages]]''' | ||
== Mechanism of action == | ==Mechanism of action== | ||
Ertapenem has in vitro activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria. The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to [[penicillin binding proteins]] (PBPs). In [[Escherichia coli]], it has strong affinity toward [[Penicillin binding proteins|PBPs]] 1a, 1b, 2, 3, 4 and 5 with preference for [[Penicillin binding proteins|PBPs]] 2 and 3. | Ertapenem has in vitro activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria. The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to [[penicillin binding proteins]] (PBPs). In [[Escherichia coli]], it has strong affinity toward [[Penicillin binding proteins|PBPs]] 1a, 1b, 2, 3, 4 and 5 with preference for [[Penicillin binding proteins|PBPs]] 2 and 3. | ||
Latest revision as of 22:17, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Overview
Ertapenem is a carbapenem antibiotic marketed by Merck as INVANZ®. It is structurally very similar to meropenem in that it possess a 1-β-methyl group.
Category
Carbapenem
US Brand Names
INVANZ®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of action
Ertapenem has in vitro activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria. The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In Escherichia coli, it has strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preference for PBPs 2 and 3.